159 related articles for article (PubMed ID: 15188223)
21. Structure activity studies on leaving group derivatives of [meso-1,2-bis-(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] platinum(II).
Gust R; Keilitz R; Krauser R; Schmidt K; Schnurr B
Arch Pharm (Weinheim); 1999 Aug; 332(8):261-70. PubMed ID: 10489536
[TBL] [Abstract][Full Text] [Related]
22. Improved synthesis of unique estradiol-linked platinum(II) complexes showing potent cytocidal activity and affinity for the estrogen receptor alpha and beta.
Descôteaux C; Leblanc V; Bélanger G; Parent S; Asselin E; Bérubé G
Steroids; 2008 Oct; 73(11):1077-89. PubMed ID: 18572212
[TBL] [Abstract][Full Text] [Related]
23. Different response of murine and human mammary tumour models to a series of diastereoisomeric [1,2-bis(difluorophenyl) ethylenediamine]dichloroplatinum(II) complexes.
Spruss T; Bernhardt G; Schickaneder E; Schönenberger H
J Cancer Res Clin Oncol; 1991; 117(5):435-43. PubMed ID: 1890139
[TBL] [Abstract][Full Text] [Related]
24. Dibenzo[a,f]quinolizines: syntheses and cytostatic activity in estrogen-sensitive tumor cells.
von Angerer S; Seidl E; Mannschreck A; von Angerer E; Wiegrebe W
Anticancer Drug Des; 1994 Feb; 9(1):25-40. PubMed ID: 8141964
[TBL] [Abstract][Full Text] [Related]
25. Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptor content of tumors.
Szepeshazi K; Schally AV; Halmos G; Szoke B; Groot K; Nagy A
Breast Cancer Res Treat; 1996; 40(2):129-39. PubMed ID: 8879679
[TBL] [Abstract][Full Text] [Related]
26. Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells.
Shields-Botella J; Chetrite G; Meschi S; Pasqualini JR
J Steroid Biochem Mol Biol; 2005 Jan; 93(1):1-13. PubMed ID: 15748827
[TBL] [Abstract][Full Text] [Related]
27. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
Lane HA; Lebwohl D
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S18-25. PubMed ID: 16730273
[TBL] [Abstract][Full Text] [Related]
28. Some aspects of the endocrine profile and management of hormone-dependent male breast cancer.
Dimitrov NV; Colucci P; Nagpal S
Oncologist; 2007 Jul; 12(7):798-807. PubMed ID: 17673611
[TBL] [Abstract][Full Text] [Related]
29. MMTV-EGF receptor transgene promotes preneoplastic conversion of multiple steroid hormone-responsive tissues.
Marozkina NV; Stiefel SM; Frierson HF; Parsons SJ
J Cell Biochem; 2008 Apr; 103(6):2010-8. PubMed ID: 17960555
[TBL] [Abstract][Full Text] [Related]
30. Synthesis of 17beta-estradiol-linked platinum(II) complexes and their cytocidal activity on estrogen-dependent and -independent breast tumor cells.
Perron V; Rabouin D; Asselin E; Parent S; C-Gaudreault R; Bérubé G
Bioorg Chem; 2005 Feb; 33(1):1-15. PubMed ID: 15668178
[TBL] [Abstract][Full Text] [Related]
31. [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] sulfatoplatinum(II)--pharmacokinetic studies.
Bernhardt G; Koch M; Spruss T; Gust R; Krauser R; Schlemmer R; Hollstein M; Lux F; Schönenberger H
Arch Pharm (Weinheim); 1999 Jun; 332(6):195-200. PubMed ID: 10399488
[TBL] [Abstract][Full Text] [Related]
32. Enantiomerically pure [1, 2-diamino-1-(4-fluorophenyl)butane]platinum(II) complexes: synthesis and antitumor activity against MCF-7 and MDA-MB 231 breast cancer and LnCaP/FGC prostate cancer cell lines.
Dullin A; Dufrasne F; Gelbcke M; Gust R
Arch Pharm (Weinheim); 2004 Dec; 337(12):654-67. PubMed ID: 15597399
[TBL] [Abstract][Full Text] [Related]
33. In vitro evaluation of dichloro-bis(pyrazole)palladium(II) and dichloro-bis(pyrazole)platinum(II) complexes as anticancer agents.
Keter FK; Kanyanda S; Lyantagaye SS; Darkwa J; Rees DJ; Meyer M
Cancer Chemother Pharmacol; 2008 Dec; 63(1):127-38. PubMed ID: 18350297
[TBL] [Abstract][Full Text] [Related]
34. Mono- and polynuclear [alkylamine]platinum(II) complexes of [1,2-bis(4-fluorophenyl)ethylenediamine]platinum(II): synthesis and investigations on cytotoxicity, cellular distribution, and DNA and protein binding.
Kapp T; Dullin A; Gust R
J Med Chem; 2006 Feb; 49(3):1182-90. PubMed ID: 16451082
[TBL] [Abstract][Full Text] [Related]
35. Combinations of interferon with platinum complexes: synergistic and antagonistic effects on growth inhibition of MCF-7 and MDA-MB231 breast cancer cells.
Otto AM
J Cancer Res Clin Oncol; 1994; 120(5):286-92. PubMed ID: 7510292
[TBL] [Abstract][Full Text] [Related]
36. Aqua[1,1-bis(4-hydroxyphenyl)-1,2-diamino-2-phenylethane]- sulfatoplatinum(II), a new compound for the treatment of the mammary carcinoma.
Gust R
Arch Pharm (Weinheim); 1994 Jan; 327(1):49-54. PubMed ID: 8117188
[TBL] [Abstract][Full Text] [Related]
37. Steroid metabolism in breast cancer.
Foster PA
Minerva Endocrinol; 2008 Mar; 33(1):27-37. PubMed ID: 18277377
[TBL] [Abstract][Full Text] [Related]
38. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
Hirokawa Y; Levitzki A; Lessene G; Baell J; Xiao Y; Zhu H; Maruta H
Cancer Lett; 2007 Jan; 245(1-2):242-51. PubMed ID: 16540233
[TBL] [Abstract][Full Text] [Related]
39. Structure-activity relationship of new trans-platinum(II) and (IV) complexes with cyclohexylamine. Interference with cell cycle progression and induction of cell death.
González-Vadillo AM; Alvarez-Valdés A; Moneo V; Blanco F; Díaz RG; Carnero A; Navarro-Ranninger C
J Inorg Biochem; 2007 Apr; 101(4):551-8. PubMed ID: 17257684
[TBL] [Abstract][Full Text] [Related]
40. Progestins and breast cancer.
Pasqualini JR
Gynecol Endocrinol; 2007 Oct; 23 Suppl 1():32-41. PubMed ID: 17943537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
